Abstract
Enterolactone (EL) is a gut microbe metabolite of the flaxseed lignan secoisolariciresinol diglucoside (SDG). Studies suggest a correlation between EL systemic levels and protective effects against cancer and cardiovascular disease. EL's oral bioavailability is low and highly variable due to extensive first-pass metabolism. To better understand the contribution of liver and intestine to first-pass glucuronidation we conducted an in vitro enzyme kinetic analysis of EL glucuronidation in liver and intestinal microsomes from both human and rat. An intrinsic clearance (CLint) value was calculated using the substrate depletion approach. In addition to monitoring substrate depletion, HPLC analysis allowed detection of EL glucuronides which were further substantiated by LC-MS/MS. EL monoglucuronide was identified in human and rat liver and intestinal microsomes. Enzyme kinetic studies indicated the extent of hepatic microsomal glucuronidation exceeded intestinal glucuronidation in both human and rat, while the human liver CLint value was slightly higher than that of rat liver. The CLint value generated in human intestinal microsomes was only one third of human liver, whereas the CLint of rat jejunum or colon was one-twentieth of rat liver suggesting the human intestine makes a greater contribution to EL glucuronidation than rat intestine. Our results suggest that both liver and intestine contribute to EL glucuronidation and the human intestine may exert a greater influence on the first-pass glucuronidation of EL than rat intestine. The rat might underestimate the extent of intestinal metabolism of EL relative to human.
Keywords: Enterolactone, flaxseed, glucuronidation, intestine, liver, lignan.
The Natural Products Journal
Title:The Comparison of Rat and Human Intestinal and Hepatic Glucuronidation of Enterolactone Derived from Flaxseed Lignans
Volume: 3 Issue: 3
Author(s): Chaojie Lin, Ed S Krol and Jane Alcorn
Affiliation:
Keywords: Enterolactone, flaxseed, glucuronidation, intestine, liver, lignan.
Abstract: Enterolactone (EL) is a gut microbe metabolite of the flaxseed lignan secoisolariciresinol diglucoside (SDG). Studies suggest a correlation between EL systemic levels and protective effects against cancer and cardiovascular disease. EL's oral bioavailability is low and highly variable due to extensive first-pass metabolism. To better understand the contribution of liver and intestine to first-pass glucuronidation we conducted an in vitro enzyme kinetic analysis of EL glucuronidation in liver and intestinal microsomes from both human and rat. An intrinsic clearance (CLint) value was calculated using the substrate depletion approach. In addition to monitoring substrate depletion, HPLC analysis allowed detection of EL glucuronides which were further substantiated by LC-MS/MS. EL monoglucuronide was identified in human and rat liver and intestinal microsomes. Enzyme kinetic studies indicated the extent of hepatic microsomal glucuronidation exceeded intestinal glucuronidation in both human and rat, while the human liver CLint value was slightly higher than that of rat liver. The CLint value generated in human intestinal microsomes was only one third of human liver, whereas the CLint of rat jejunum or colon was one-twentieth of rat liver suggesting the human intestine makes a greater contribution to EL glucuronidation than rat intestine. Our results suggest that both liver and intestine contribute to EL glucuronidation and the human intestine may exert a greater influence on the first-pass glucuronidation of EL than rat intestine. The rat might underestimate the extent of intestinal metabolism of EL relative to human.
Export Options
About this article
Cite this article as:
Lin Chaojie, Krol S Ed and Alcorn Jane, The Comparison of Rat and Human Intestinal and Hepatic Glucuronidation of Enterolactone Derived from Flaxseed Lignans, The Natural Products Journal 2013; 3 (3) . https://dx.doi.org/10.2174/2210315511303030001
DOI https://dx.doi.org/10.2174/2210315511303030001 |
Print ISSN 2210-3155 |
Publisher Name Bentham Science Publisher |
Online ISSN 2210-3163 |
Call for Papers in Thematic Issues
Ayurvedic medicinal therapeutic approaches for inflammatory and neurodegenerative disorders
Usually, in our elderly population, neurodegenerative disorders occur due to neuron death. Alzheimer?s disease (AD) is an irreversible and progressive neurodegenerative disease. Dementia is the leading cause of AD, which affects about 30 million people worldwide. According to the World Alzheimer report 2018, a new case of dementia develops every ...read more
Recent Advances in Biotransformation of Bioactive Terpenoids using Aspergillus niger
Biotransformation is the reaction catalyzed by biological catalysts of either isolated enzymes or whole cell cultures of microorganisms. This process has been extensively applied in the conversion of bioactive terpenoids with high regio- and stereospecifity. This process has been also applied in the lead discovery and development. Aspergillus niger has ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Screening for Silent Coronary Artery Disease in Diabetics- or Not?
Current Diabetes Reviews Potential Applications for Using Stem Cells in Spine Surgery
Current Stem Cell Research & Therapy Perioperative Considerations in Rheumatoid Arthritis Patients
Current Rheumatology Reviews Therapeutic Potential for Thyroid Hormone Receptor-β Selective Agonists for Treating Obesity, Hyperlipidemia and Diabetes
Current Vascular Pharmacology Blockade of Renin Angiotensin System in Heart Failure Post-Myocardial Infarction: What is the Best Therapy?
Recent Patents on Cardiovascular Drug Discovery Challenges and Perspectives of Antiplatelet Therapy in Patients with Diabetes Mellitus and Coronary Artery Disease
Current Pharmaceutical Design Cardiomyocyte-Specific TβR2 Knockout Mice are More Susceptible to Cardiac Hypertrophy Induced by Adrenergic Agonist Stimulation
Current Molecular Medicine Treatment of Experimental Myocarditis via Modulation of the Renin-Angiotensin System
Current Pharmaceutical Design Editorial (Towards Better Understanding on Psychiatric Disorder, Ocular Diseases, Heart Disease and Cancer)
Current Molecular Medicine A Therapeutic Target of Cerebral Hemorrhagic Stroke: Matrix Metalloproteinase- 9
Current Drug Targets Omega-3 Fatty Acids: Repurposing Opportunities for Cognition and Biobehavioral Disturbances in MCI and Dementia
Current Alzheimer Research Why is the Incidence of Type 1 Diabetes Increasing?
Current Diabetes Reviews Acute and Subacute Toxicity Study on Dietary Supplementation with Soy Isoflavones in Wistar Rats
Current Nutrition & Food Science Reactive Oxygen Species in the Initiation of IL-4 Driven Autoimmunity as a Potential Therapeutic Target
Current Pharmaceutical Design The Role of Diet in Patients with Metabolic Syndrome
Current Medicinal Chemistry Association Between the Levels of Circulating Adhesion Molecules and Biopterins in Type-2 Diabetic Normotensive Patients Adhesion Molecules and Biopterins
Endocrine, Metabolic & Immune Disorders - Drug Targets Relationship between Augmentation Index and Wall Thickening Fraction during Hypotension in an Animal Model of Myocardial Ischemia-Reperfusion and Heart Failure
Current Hypertension Reviews Haptoglobin Polymorphism and Lacunar Stroke
Current Neurovascular Research Antiplatelet Therapy in Acute Coronary Syndromes. Evidence Based Medicine
Current Pharmaceutical Design A Novel Treatment Strategy for Sepsis and Septic Shock Based on the Interactions between Prostanoids, Nitric Oxide, and 20-Hydroxyeicosatetraenoic Acid
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry